Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Pedmark First Drug Approved for Hearing Loss Prevention in Children with Solid Tumors

JHOP - October 2022 Vol 12, No 5 - FDA Oncology Update
NEW DRUGS

On September 20, 2022, the FDA approved sodium thiosulfate (Pedmark; Fennec Pharmaceuticals), an inorganic sodium salt, for risk reduction of hearing loss (ototoxicity) associated with cisplatin treatment in children aged ≥1 month to 18 years with nonmetastatic solid tumors. Sodium thiosulfate received an orphan drug designation for this indication.

The safety and efficacy of sodium thiosulfate when used after cisplatin infusions for ≥6 hours have not been determined; if hearing loss had already occurred, this drug may not reduce its risk after long cisplatin infusions.

This approval was based on the results of 2 phase 3 clinical trials: the multicenter, open-label, randomized controlled SIOPEL 6 and the Clinical Oncology Group (COG) ACCL0431. The SIOPEL 6 study included 114 pediatric patients with standard-risk hepatoblastoma who had received perioperative cisplatin-based chemotherapy. The main end point was the percentage of patients with Brock grade ≥1 hearing loss. The incidence of hearing loss was lower in the sodium thiosulfate plus cisplatin arm than in the cisplatin monotherapy arm (39% vs 68%, respectively; relative risk [RR], 0.58; 95% confidence interval [CI], 0.40-0.83).

The COG ACCL0431 study included 125 pediatric patients with solid tumors who received cumulative cisplatin doses of ≥200 mg/m2, with individual cisplatin doses infused over ≤6 hours. The incidence of hearing loss was lower in the sodium thiosulfate plus cisplatin arm than in the cisplatin monotherapy arm (44% vs 58%, respectively; RR, 0.75; 95% CI, 0.48-1.18).

The most common (≥25% with a between-arms difference of >5% vs cisplatin monotherapy) adverse reactions in both trials were vomiting, nausea, decreased hemoglobin, hypernatremia, and hypokalemia.

Related Items
Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pemazyre Receives New Indication for FGFR1-­Positive Myeloid/Lymphoid Neoplasms
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.